期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 58, 期 24, 页码 9421-9437出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.5b00326
关键词
-
资金
- Foundation Solidar-Immun (Lausanne, Switzerland)
Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies. Many novel IDO1 inhibitor scaffolds have been described, and a few potent compounds have entered clinical trials. However, a significant number of the reported compounds contain problematic functional groups, suggesting that enzyme inhibition could be the result of undesirable side reactions instead of selective binding to IDO1 Here, we describe issues in the employed experimental protocols, review and classify reported IDO1 inhibitors, and suggest different approaches for confirming viable inhibitor scaffolds.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据